Precision Psychiatry Market Size, Share and Growth Outlook 2026: By Service and Diagnostics Type (Genetic Testing, Biomarker Analysis, Data Analytics and Interpretation Services), By Technology, By Therapeutic Area, By End User, Companies to 2034.
The global Precision Psychiatry Market size is forecast to increase from $1050.71 Million in 2026 to $3367.04 Million in 2034 at a CAGR of 15.67% between 2026 and 2034.
The Precision Psychiatry market report provides detailed analysis and outlook of Precision Psychiatry segments including By Service and Diagnostics Type (Genetic Testing, Biomarker Analysis, Data Analytics and Interpretation Services), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassay, Mass Spectrometry), By Therapeutic Area (Depression and Anxiety Disorders, Schizophrenia and Psychotic Disorders, Bipolar Disorder, Substance Use Disorders), By End User (Hospitals and Clinics, Clinical Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Precision Psychiatry Industry Overview
Biomarker-Driven Therapeutics, Psychedelic Medicine, and Patient Stratification are Transforming the Precision Psychiatry Industry
The Precision Psychiatry industry is undergoing a fundamental shift from symptom-based treatment paradigms toward biologically informed, patient-specific therapeutic strategies. Advances in neurobiology, molecular diagnostics, neuroimaging, immunopsychiatry, and psychedelic-assisted therapies are enabling clinicians and drug developers to identify distinct biological subtypes within traditionally heterogeneous psychiatric disorders. This transition is accelerating investment in precision biomarkers, targeted neurotherapeutics, and personalized treatment algorithms designed to improve remission rates in conditions such as major depressive disorder, generalized anxiety disorder, psychosis, and treatment-resistant psychiatric illnesses. Regulatory agencies, pharmaceutical companies, and academic research networks are increasingly supporting precision-based approaches that combine biological profiling with individualized therapeutic interventions.
Precision Therapeutics and Psychedelic Medicines are Expanding Late-Stage Psychiatric Drug Development
One of the most significant trends shaping the precision psychiatry market is the advancement of targeted neuropsychiatric therapies designed around underlying biological mechanisms rather than broad diagnostic classifications. Clinical development programs are increasingly incorporating patient stratification frameworks, biomarker monitoring, and personalized treatment endpoints into late-stage trials. This trend is illustrated by the strategic transition of Mind Medicine into Definium Therapeutics, which accompanies the advancement of its lead candidate DT1201 ODT into four concurrent Phase 3 clinical programs targeting generalized anxiety disorder and major depressive disorder using biologically informed remission tracking approaches. Similarly, the rapid maturation of psychedelic medicine platforms is reshaping psychiatric therapeutics development. Compass Pathways' progress toward regulatory submission of COMP360 demonstrates the growing institutional and regulatory acceptance of precision-guided psychedelic therapies, supported by expanding outpatient treatment infrastructures designed to integrate specialized psychiatric monitoring and administration workflows.
Biomarker Discovery and Immunopsychiatry are Creating New Diagnostic Frameworks
The precision psychiatry industry is also witnessing substantial progress in biological patient stratification and disease mechanism identification. Researchers are increasingly recognizing that psychiatric disorders often encompass multiple underlying biological subtypes that require distinct therapeutic approaches. This emerging paradigm is exemplified by collaborative initiatives supported through the Precision Mind Prize, involving organizations including the NIHR Mental Health Translational Research Collaboration, Wakam, and the FondaMental Foundation. Projects such as AUTOSCREEN utilize advanced technologies including lab-grown human neuronal models and super-resolution microscopy to identify autoimmune biomarkers associated with psychiatric symptoms. These efforts support the development of immunopsychiatry frameworks capable of distinguishing patients whose psychiatric manifestations originate from immune dysfunction, potentially enabling more precise diagnosis, targeted treatment selection, and improved clinical outcomes across complex mental health disorders.
Precision Psychiatry Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Precision Psychiatry market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Illumina, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Genomind, Inc., Bio-Rad Laboratories, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., GeneDx, LLC. The Precision Psychiatry market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Precision Psychiatry industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Precision Psychiatry industry include- Illumina, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Genomind, Inc., Bio-Rad Laboratories, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., GeneDx, LLC. The Precision Psychiatry market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Precision Psychiatry Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Precision Psychiatry market remains one of the strongest-performing segments in the country.
The US Precision Psychiatry Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Precision Psychiatry market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Precision Psychiatry industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Precision Psychiatry markets
Canada's strong Precision Psychiatry sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Precision Psychiatry market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Precision Psychiatry Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Precision Psychiatry market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Precision Psychiatry population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Precision Psychiatry industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Precision Psychiatry market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Precision Psychiatry sales through 2034
France Precision Psychiatry companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Precision Psychiatry Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Precision Psychiatry distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Precision Psychiatry Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Precision Psychiatry market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Precision Psychiatry industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Precision Psychiatry industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Precision Psychiatry Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Precision Psychiatry market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Precision Psychiatry market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Precision Psychiatry Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Precision Psychiatry Market Segmentation
By Service and Diagnostics Type
Genetic Testing
Biomarker Analysis
Data Analytics and Interpretation Services
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Immunoassay
Mass Spectrometry
By Therapeutic Area
Depression and Anxiety Disorders
Schizophrenia and Psychotic Disorders
Bipolar Disorder
Substance Use Disorders
By End User
Hospitals and Clinics
Clinical Laboratories
Leading Companies in Precision Psychiatry Industry (2026)
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Myriad Genetics, Inc.
Laboratory Corporation of America Holdings (Labcorp)
Quest Diagnostics Incorporated
Genomind, Inc.
Bio-Rad Laboratories, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
GeneDx, LLC
Countries Included
The Precision Psychiatry market report provides detailed analysis and outlook of Precision Psychiatry segments including By Service and Diagnostics Type (Genetic Testing, Biomarker Analysis, Data Analytics and Interpretation Services), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassay, Mass Spectrometry), By Therapeutic Area (Depression and Anxiety Disorders, Schizophrenia and Psychotic Disorders, Bipolar Disorder, Substance Use Disorders), By End User (Hospitals and Clinics, Clinical Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Precision Psychiatry Industry Overview
Biomarker-Driven Therapeutics, Psychedelic Medicine, and Patient Stratification are Transforming the Precision Psychiatry Industry
The Precision Psychiatry industry is undergoing a fundamental shift from symptom-based treatment paradigms toward biologically informed, patient-specific therapeutic strategies. Advances in neurobiology, molecular diagnostics, neuroimaging, immunopsychiatry, and psychedelic-assisted therapies are enabling clinicians and drug developers to identify distinct biological subtypes within traditionally heterogeneous psychiatric disorders. This transition is accelerating investment in precision biomarkers, targeted neurotherapeutics, and personalized treatment algorithms designed to improve remission rates in conditions such as major depressive disorder, generalized anxiety disorder, psychosis, and treatment-resistant psychiatric illnesses. Regulatory agencies, pharmaceutical companies, and academic research networks are increasingly supporting precision-based approaches that combine biological profiling with individualized therapeutic interventions.
Precision Therapeutics and Psychedelic Medicines are Expanding Late-Stage Psychiatric Drug Development
One of the most significant trends shaping the precision psychiatry market is the advancement of targeted neuropsychiatric therapies designed around underlying biological mechanisms rather than broad diagnostic classifications. Clinical development programs are increasingly incorporating patient stratification frameworks, biomarker monitoring, and personalized treatment endpoints into late-stage trials. This trend is illustrated by the strategic transition of Mind Medicine into Definium Therapeutics, which accompanies the advancement of its lead candidate DT1201 ODT into four concurrent Phase 3 clinical programs targeting generalized anxiety disorder and major depressive disorder using biologically informed remission tracking approaches. Similarly, the rapid maturation of psychedelic medicine platforms is reshaping psychiatric therapeutics development. Compass Pathways' progress toward regulatory submission of COMP360 demonstrates the growing institutional and regulatory acceptance of precision-guided psychedelic therapies, supported by expanding outpatient treatment infrastructures designed to integrate specialized psychiatric monitoring and administration workflows.
Biomarker Discovery and Immunopsychiatry are Creating New Diagnostic Frameworks
The precision psychiatry industry is also witnessing substantial progress in biological patient stratification and disease mechanism identification. Researchers are increasingly recognizing that psychiatric disorders often encompass multiple underlying biological subtypes that require distinct therapeutic approaches. This emerging paradigm is exemplified by collaborative initiatives supported through the Precision Mind Prize, involving organizations including the NIHR Mental Health Translational Research Collaboration, Wakam, and the FondaMental Foundation. Projects such as AUTOSCREEN utilize advanced technologies including lab-grown human neuronal models and super-resolution microscopy to identify autoimmune biomarkers associated with psychiatric symptoms. These efforts support the development of immunopsychiatry frameworks capable of distinguishing patients whose psychiatric manifestations originate from immune dysfunction, potentially enabling more precise diagnosis, targeted treatment selection, and improved clinical outcomes across complex mental health disorders.
Precision Psychiatry Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Precision Psychiatry market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Illumina, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Genomind, Inc., Bio-Rad Laboratories, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., GeneDx, LLC. The Precision Psychiatry market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Precision Psychiatry industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Precision Psychiatry Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Precision Psychiatry companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Precision Psychiatry markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Precision Psychiatry industry include- Illumina, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Genomind, Inc., Bio-Rad Laboratories, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., GeneDx, LLC. The Precision Psychiatry market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Precision Psychiatry Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Precision Psychiatry market remains one of the strongest-performing segments in the country.
The US Precision Psychiatry Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Precision Psychiatry market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Precision Psychiatry industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Precision Psychiatry markets
Canada's strong Precision Psychiatry sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Precision Psychiatry market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Precision Psychiatry Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Precision Psychiatry market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Precision Psychiatry population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Precision Psychiatry industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Precision Psychiatry market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Precision Psychiatry sales through 2034
France Precision Psychiatry companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Precision Psychiatry Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Precision Psychiatry distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Precision Psychiatry Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Precision Psychiatry market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Precision Psychiatry industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Precision Psychiatry industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Precision Psychiatry Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Precision Psychiatry market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Precision Psychiatry market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Precision Psychiatry Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Precision Psychiatry Market Segmentation
By Service and Diagnostics Type
Genetic Testing
Biomarker Analysis
Data Analytics and Interpretation Services
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Immunoassay
Mass Spectrometry
By Therapeutic Area
Depression and Anxiety Disorders
Schizophrenia and Psychotic Disorders
Bipolar Disorder
Substance Use Disorders
By End User
Hospitals and Clinics
Clinical Laboratories
Leading Companies in Precision Psychiatry Industry (2026)
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Myriad Genetics, Inc.
Laboratory Corporation of America Holdings (Labcorp)
Quest Diagnostics Incorporated
Genomind, Inc.
Bio-Rad Laboratories, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
GeneDx, LLC
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Precision Psychiatry Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Precision Psychiatry Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL PRECISION PSYCHIATRY MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Precision Psychiatry Markets in 2026
3.2. Global Historic and Forecast Precision Psychiatry Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Precision Psychiatry Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Precision Psychiatry Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Precision Psychiatry Value Chain
CHAPTER 4- PRECISION PSYCHIATRY MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Precision Psychiatry Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- PRECISION PSYCHIATRY MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Service and Diagnostics Type
Genetic Testing
Biomarker Analysis
Data Analytics and Interpretation Services
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Immunoassay
Mass Spectrometry
By Therapeutic Area
Depression and Anxiety Disorders
Schizophrenia and Psychotic Disorders
Bipolar Disorder
Substance Use Disorders
By End User
Hospitals and Clinics
Clinical Laboratories
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Precision Psychiatry Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Precision Psychiatry Market Trends and Growth Opportunities to 2034
7.5. North America Precision Psychiatry Market Size Outlook by Type
7.6. North America Precision Psychiatry Market Size Outlook by Application
7.7. North America Precision Psychiatry Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Precision Psychiatry Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Precision Psychiatry Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Precision Psychiatry Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Precision Psychiatry Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Precision Psychiatry Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Precision Psychiatry Companies
CHAPTER 8- EUROPE PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Precision Psychiatry Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Precision Psychiatry Market Trends and Growth Opportunities to 2034
8.5. Europe Precision Psychiatry Market Size Outlook by Type
8.6. Europe Precision Psychiatry Market Size Outlook by Application
8.7. Europe Precision Psychiatry Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Precision Psychiatry Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Precision Psychiatry Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Precision Psychiatry Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Precision Psychiatry Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Precision Psychiatry Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Precision Psychiatry Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Precision Psychiatry Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Precision Psychiatry Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Precision Psychiatry Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Precision Psychiatry Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Precision Psychiatry Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Precision Psychiatry Companies
CHAPTER 9- ASIA PACIFIC PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Precision Psychiatry Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Precision Psychiatry Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Precision Psychiatry Market Size Outlook by Type
9.6. Asia Pacific Precision Psychiatry Market Size Outlook by Application
9.7. Asia Pacific Precision Psychiatry Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Precision Psychiatry Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Precision Psychiatry Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Precision Psychiatry Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Precision Psychiatry Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Precision Psychiatry Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Precision Psychiatry Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Precision Psychiatry Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Precision Psychiatry Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Precision Psychiatry Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Precision Psychiatry Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Precision Psychiatry Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Precision Psychiatry Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Precision Psychiatry Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Precision Psychiatry Market Trends and Growth Opportunities to 2034
10.5. South and Central America Precision Psychiatry Market Size Outlook by Type
10.6. South and Central America Precision Psychiatry Market Size Outlook by Application
10.7. South and Central America Precision Psychiatry Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Precision Psychiatry Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Precision Psychiatry Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Precision Psychiatry Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Precision Psychiatry Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Precision Psychiatry Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Precision Psychiatry Companies
CHAPTER 11- MIDDLE EAST AND AFRICA PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Precision Psychiatry Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Precision Psychiatry Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Precision Psychiatry Market Size Outlook by Type
11.6. Middle East and Africa Precision Psychiatry Market Size Outlook by Application
11.7. Middle East and Africa Precision Psychiatry Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Precision Psychiatry Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Precision Psychiatry Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Precision Psychiatry Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Precision Psychiatry Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Precision Psychiatry Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Precision Psychiatry Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Precision Psychiatry Industry
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Myriad Genetics, Inc.
Laboratory Corporation of America Holdings (Labcorp)
Quest Diagnostics Incorporated
Genomind, Inc.
Bio-Rad Laboratories, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
GeneDx, LLC
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Precision Psychiatry Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Precision Psychiatry Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL PRECISION PSYCHIATRY MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Precision Psychiatry Markets in 2026
3.2. Global Historic and Forecast Precision Psychiatry Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Precision Psychiatry Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Precision Psychiatry Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Precision Psychiatry Value Chain
CHAPTER 4- PRECISION PSYCHIATRY MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Precision Psychiatry Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- PRECISION PSYCHIATRY MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Service and Diagnostics Type
Genetic Testing
Biomarker Analysis
Data Analytics and Interpretation Services
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Immunoassay
Mass Spectrometry
By Therapeutic Area
Depression and Anxiety Disorders
Schizophrenia and Psychotic Disorders
Bipolar Disorder
Substance Use Disorders
By End User
Hospitals and Clinics
Clinical Laboratories
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Precision Psychiatry Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Precision Psychiatry Market Trends and Growth Opportunities to 2034
7.5. North America Precision Psychiatry Market Size Outlook by Type
7.6. North America Precision Psychiatry Market Size Outlook by Application
7.7. North America Precision Psychiatry Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Precision Psychiatry Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Precision Psychiatry Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Precision Psychiatry Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Precision Psychiatry Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Precision Psychiatry Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Precision Psychiatry Companies
CHAPTER 8- EUROPE PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Precision Psychiatry Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Precision Psychiatry Market Trends and Growth Opportunities to 2034
8.5. Europe Precision Psychiatry Market Size Outlook by Type
8.6. Europe Precision Psychiatry Market Size Outlook by Application
8.7. Europe Precision Psychiatry Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Precision Psychiatry Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Precision Psychiatry Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Precision Psychiatry Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Precision Psychiatry Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Precision Psychiatry Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Precision Psychiatry Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Precision Psychiatry Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Precision Psychiatry Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Precision Psychiatry Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Precision Psychiatry Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Precision Psychiatry Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Precision Psychiatry Companies
CHAPTER 9- ASIA PACIFIC PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Precision Psychiatry Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Precision Psychiatry Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Precision Psychiatry Market Size Outlook by Type
9.6. Asia Pacific Precision Psychiatry Market Size Outlook by Application
9.7. Asia Pacific Precision Psychiatry Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Precision Psychiatry Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Precision Psychiatry Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Precision Psychiatry Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Precision Psychiatry Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Precision Psychiatry Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Precision Psychiatry Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Precision Psychiatry Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Precision Psychiatry Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Precision Psychiatry Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Precision Psychiatry Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Precision Psychiatry Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Precision Psychiatry Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Precision Psychiatry Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Precision Psychiatry Market Trends and Growth Opportunities to 2034
10.5. South and Central America Precision Psychiatry Market Size Outlook by Type
10.6. South and Central America Precision Psychiatry Market Size Outlook by Application
10.7. South and Central America Precision Psychiatry Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Precision Psychiatry Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Precision Psychiatry Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Precision Psychiatry Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Precision Psychiatry Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Precision Psychiatry Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Precision Psychiatry Companies
CHAPTER 11- MIDDLE EAST AND AFRICA PRECISION PSYCHIATRY MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Precision Psychiatry Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Precision Psychiatry Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Precision Psychiatry Market Size Outlook by Type
11.6. Middle East and Africa Precision Psychiatry Market Size Outlook by Application
11.7. Middle East and Africa Precision Psychiatry Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Precision Psychiatry Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Precision Psychiatry Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Precision Psychiatry Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Precision Psychiatry Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Precision Psychiatry Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Precision Psychiatry Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Precision Psychiatry Industry
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Myriad Genetics, Inc.
Laboratory Corporation of America Holdings (Labcorp)
Quest Diagnostics Incorporated
Genomind, Inc.
Bio-Rad Laboratories, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
GeneDx, LLC
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
